title: Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
abstract: In order to investigate the changes of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in residual hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE), the expression levels of VEGF and bFGF expression in specimens surgically removed from 48 HCC patients were detected by immunohistochemical methods, and staining intensity of VEGF and bFGF was assessed by a computer-assisted image-analyzer. Among the 48 patients, 25 underwent partial hepatectomy alone (single operating group), and 23 were subjected to second stage surgical resection after TACE (TACE group). The results showed that the average absorbance value (A) of VEGF was higher in TACE group than that in single operating group (0.152 +/- 0.021 vs 0.131 +/- 0.012, P < 0.01). The Average A of bF-GF in TACE group was 0.127 +/- 0.023, higher than in single operating group (0.111 +/- 0.016, P < 0.05). These results suggested that TACE of HCC can up-regulate the expression of VEGF and bFGF in HCC tissues possibly due to anoxia and ischemia.
authors.affiliation: Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Liao
authors.forename: Jilin
authors.initials: J
authors.lastname: Yi
authors.forename: Xingrui
authors.initials: X
authors.lastname: Li
authors.forename: Zhifang
authors.initials: Z
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Deng
authors.forename: Geng
authors.initials: G
authors.lastname: Tian
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D002406:Catheterization, Peripheral; D016461:Chemoembolization, Therapeutic; D003515:Cycloleucine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000032:analysis*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
chemical_list: D042461:Vascular Endothelial Growth Factor A; D003515:Cycloleucine; D016222:Fibroblast Growth Factor 2; C065594:cispentacin; D016685:Mitomycin; D005472:Fluorouracil